Altimmune Historical Cash Flow
| ALT Stock | USD 8.25 0.07 0.86% |
Analysis of Altimmune cash flow over time is an excellent tool to project Altimmune future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Change In Cash of 16.3 M or Capital Expenditures of 44.6 K as it is a great indicator of Altimmune ability to facilitate future growth, repay debt on time or pay out dividends.
Financial Statement Analysis is much more than just reviewing and examining Altimmune latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Altimmune is a good buy for the upcoming year.
Altimmune |
About Altimmune Cash Flow Analysis
The Cash Flow Statement is a financial statement that shows how changes in Altimmune balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Altimmune's non-liquid assets can be easily converted into cash.
Altimmune Cash Flow Chart
Add Fundamental
Capital Expenditures
Capital Expenditures are funds used by Altimmune to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of Altimmune operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.Begin Period Cash Flow
The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.Depreciation
Depreciation indicates how much of Altimmune value has been used up. For tax purposes Altimmune can deduct the cost of the tangible assets it purchases as business expenses. However, Altimmune must depreciate these assets in accordance with IRS rules about how and when the deduction may be taken, and how long it will last. The systematic allocation of the cost of a tangible asset over its useful life.Stock Based Compensation
Compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders.Most accounts from Altimmune's cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into Altimmune current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Altimmune. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. For more information on how to buy Altimmune Stock please use our How to Invest in Altimmune guide.At this time, Altimmune's Change To Netincome is comparatively stable compared to the past year. Change To Liabilities is likely to gain to about 3.3 M in 2024, despite the fact that Free Cash Flow is likely to grow to (72.1 M).
| 2021 | 2022 | 2023 | 2024 (projected) | Begin Period Cash Flow | 116.0M | 190.3M | 111.1M | 116.7M | End Period Cash Flow | 190.3M | 111.1M | 135.2M | 141.9M |
Altimmune cash flow statement Correlations
Click cells to compare fundamentals
Altimmune Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Altimmune cash flow statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Sale Purchase Of Stock | 3.8B | 135.5M | 224.5M | (516K) | 215K | 204.3K | |
| Change In Cash | (25.4M) | 107.0M | 74.4M | (79.2M) | 24.0M | 16.3M | |
| Free Cash Flow | (9.6M) | (34.8M) | (90.5M) | (62.7M) | (75.9M) | (72.1M) | |
| Change In Working Capital | 1.8M | (4.5M) | (250.5K) | 14.1M | (8.3M) | (7.9M) | |
| Other Cashflows From Financing Activities | 155.3K | 41.8M | 58K | 434K | (711K) | (675.5K) | |
| Capital Expenditures | 29.0K | 342.4K | 12.3M | 126K | 47K | 44.7K | |
| Total Cash From Operating Activities | (9.6M) | (34.4M) | (78.2M) | (62.6M) | (75.8M) | (72.0M) | |
| Net Income | (20.5M) | (49.0M) | (97.1M) | (84.7M) | (88.4M) | (84.0M) | |
| Total Cash From Financing Activities | 12.5M | 213.5M | 65.1M | 56.8M | 86.1M | 90.4M | |
| End Period Cash Flow | 9.0M | 116.0M | 190.3M | 111.1M | 135.2M | 141.9M | |
| Begin Period Cash Flow | 34.4M | 9.0M | 116.0M | 190.3M | 111.1M | 116.7M | |
| Change To Inventory | (4.1M) | 5.6M | (288.8K) | 1.0 | 1.15 | 1.21 | |
| Depreciation | 387.3K | 298.1K | 551.3K | (205K) | 477K | 315.0K | |
| Other Non Cash Items | 7.5M | 16.3M | 700K | 120K | 9.8M | 9.3M | |
| Change To Account Receivables | 2.4M | (3.6M) | 4.2M | 256K | (2.3M) | (2.2M) | |
| Stock Based Compensation | 1.3M | 2.6M | 5.5M | 8.1M | 10.6M | 11.2M | |
| Investments | (28.3M) | (71.8M) | 99.8M | (73.4M) | 13.7M | 14.4M | |
| Change Receivables | 344.3K | 2.4M | (3.6M) | 4.2M | 3.8M | 4.0M | |
| Total Cashflows From Investing Activities | (28.3M) | (72.1M) | 87.5M | (73.4M) | (66.1M) | (62.8M) | |
| Cash And Cash Equivalents Changes | 22.1M | (25.4M) | 107.0M | 74.4M | 85.5M | 89.8M | |
| Cash Flows Other Operating | 9.3M | 534.9K | (8.5M) | (3.6M) | (3.2M) | (3.0M) | |
| Other Cashflows From Investing Activities | (27.8K) | (138.5K) | (194.5K) | (73.3M) | (65.9M) | (62.6M) | |
| Change To Netincome | 8.7M | 18.8M | 18.6M | 8.2M | 9.5M | 10.3M | |
| Change To Liabilities | (1.2M) | 7.6M | (877.2K) | 2.8M | 3.2M | 3.3M | |
| Change To Operating Activities | (668.7K) | 5.6M | (8.2M) | 8.0M | 9.2M | 9.7M | |
| Issuance Of Capital Stock | 12.7M | 172.3M | 65.0M | 56.3M | 86.8M | 78.9M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Altimmune Stock Analysis
When running Altimmune's price analysis, check to measure Altimmune's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Altimmune is operating at the current time. Most of Altimmune's value examination focuses on studying past and present price action to predict the probability of Altimmune's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Altimmune's price. Additionally, you may evaluate how the addition of Altimmune to your portfolios can decrease your overall portfolio volatility.